Denosumab for management of parathyroid carcinoma-mediated hypercalcemia

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages 387-390

  Vellanki, Priyathama ^a   Lange, Karoline ^b   Elaraj, Dina ^a   Kopp, Peter A ^a   Muayed, Malek El ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA; HUMANS; HYPERCALCEMIA; MALE; PARATHYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84893808437     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3031     Document Type: Article

References (15)

1. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359-372.
2. Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991; 15:738-744.
3. Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13:11-23.
4. Holmes EC, Morton DL, Ketcham AS. Parathyroid carcinoma: a collective review. Ann Surg. 1969;169:631-640.
5. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992;71:197-205.
6. Newrick PG, Braatvedt GD, Webb AJ, Sheffield E, Corrall RJ. Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. Postgrad Med J. 1994;70:231-232.
7. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab. 1998;83:1083-1088.
8. Calandra DB, Chejfec G, Foy BK, Lawrence AM, Paloyan E. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery. 1984;96:1132-1137.
9. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
10. Sun L,YuS. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and metaanalysis. Am J Clin Oncol. 2013;36:399-403.
11. HenryDH,Costa L,GoldwasserF, et al.Randomized,double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-1132.
12. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813-822.
13. Bech A, de Boer H. Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med. 2012;156:906-907.
14. Boikos SA, Hammers HJ. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia. J Clin Oncol. 2012;30:e299.
15. Khoury N, Chang J, Gru AA, Whyte MP. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab. J Clin Endocrinol Metab. 2012;97:3051-3055.